Drugs & Targets FDA grants Imfinzi priority review and Breakthrough Therapy designation for limited-stage SCLC September 06, 2024Vol.50 No.33
Drugs & Targets NCCN adds Lymphir to Clinical Practice Guidelines in Oncology September 06, 2024Vol.50 No.33
Drugs & Targets EC approves Padcev + Keytruda for advanced urothelial cancer September 06, 2024Vol.50 No.33
Drugs & Targets EC approves Lynparza + Imfinzi for pMMR endometrial cancer September 06, 2024Vol.50 No.33
Drugs & Targets EC grants conditional marketing authorization for Tepkinly for r/r FL September 06, 2024Vol.50 No.33
Drugs & Targets FDA grants de novo authorization for PGDx elio plasma focus Dx, a kitted, pan-solid tumor liquid biopsy test August 09, 2024Vol.50 No.32
Drugs & Targets Daiichi Sankyo, Merck collaborate to develop and commercialize MK-6070, an investigational delta-like ligand 3 targeting T-cell engager August 09, 2024Vol.50 No.32
